ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response
The tyrosine kinase inhibitor STI571 (imatinib mesylate, Gleevec) is an effective treatment for chronic myeloid leukemia (CML). We examined bone marrow samples from 53 patients with CML who were receiving STI571 in 3 multicenter phase 2 trials to assess morphologic changes and cytogenetic response t...
Gespeichert in:
| Veröffentlicht in: | American journal of clinical pathology 2002-03, Vol.117 (3), p.360-367 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 367 |
|---|---|
| container_issue | 3 |
| container_start_page | 360 |
| container_title | American journal of clinical pathology |
| container_volume | 117 |
| creator | Hasserjian, Robert P Boecklin, Federica Parker, Sally Chase, Andy Dhar, Sunanda Zaiac, Michael Olavarria, Eduardo Lampert, Irvin Henry, Kristin Apperley, Jane F Goldman, John M |
| description | The tyrosine kinase inhibitor STI571 (imatinib mesylate, Gleevec) is an effective treatment for chronic myeloid leukemia (CML). We examined bone marrow samples from 53 patients with CML who were receiving STI571 in 3 multicenter phase 2 trials to assess morphologic changes and cytogenetic response to this drug. In most patients with initially increased blasts, the bone marrow blast count rapidly decreased during STI571 therapy. Reductions in cellularity, the myeloid/erythroid ratio (commonly with relative erythroid hyperplasia), and reticulin fibrosis (if present pretreatment) also were seen in most patients, resulting in an appearance resembling normal marrow in many cases. Eighteen patients (34%) had some degree of cytogenetic response. Surprisingly, these striking morphologic changes occurred irrespective of any cytogenetic response to STI571. Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibitfeatures resembling normal hematopoiesis. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71500719</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71500719</sourcerecordid><originalsourceid>FETCH-LOGICAL-p545-830d01e9e4775fe415f9ff9ee47a6de2506414cb362043e67142c9312931de643</originalsourceid><addsrcrecordid>eNo1kE9LxDAQxXtQ3HX1K0hOoodC0iZNe5TFf7Dgwd5Lmk7WSJrUJFXq1S9uFtfDvGFmfjyYd5KtMcZF3hBerrLzEN4xJkWN6Vm2IqSua8zZOvt5bQnjBN3oUURtdY9GCIsREW6Rh2GWEFDvLKBReO--kARjZiO8jgsSdkDW-VEY_Z2w0fnpzRm31xIpEHH2aal90glk1J-AnEJyiW4PFmKCDhdnA1xkp0qYAJfHvsnah_t2-5TvXh6ft3e7fGKU5XWJB0ygAco5U0AJU41SDaRZVAMUDFeUUNmXVYFpCRUntJBNSYpUA1S03GTXf7aTdx8zhNiNOhz-ERbcHDpOGMacNAm8OoJzP8LQTT6F45fuP7XyF7TFadY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71500719</pqid></control><display><type>article</type><title>ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hasserjian, Robert P ; Boecklin, Federica ; Parker, Sally ; Chase, Andy ; Dhar, Sunanda ; Zaiac, Michael ; Olavarria, Eduardo ; Lampert, Irvin ; Henry, Kristin ; Apperley, Jane F ; Goldman, John M</creator><creatorcontrib>Hasserjian, Robert P ; Boecklin, Federica ; Parker, Sally ; Chase, Andy ; Dhar, Sunanda ; Zaiac, Michael ; Olavarria, Eduardo ; Lampert, Irvin ; Henry, Kristin ; Apperley, Jane F ; Goldman, John M</creatorcontrib><description>The tyrosine kinase inhibitor STI571 (imatinib mesylate, Gleevec) is an effective treatment for chronic myeloid leukemia (CML). We examined bone marrow samples from 53 patients with CML who were receiving STI571 in 3 multicenter phase 2 trials to assess morphologic changes and cytogenetic response to this drug. In most patients with initially increased blasts, the bone marrow blast count rapidly decreased during STI571 therapy. Reductions in cellularity, the myeloid/erythroid ratio (commonly with relative erythroid hyperplasia), and reticulin fibrosis (if present pretreatment) also were seen in most patients, resulting in an appearance resembling normal marrow in many cases. Eighteen patients (34%) had some degree of cytogenetic response. Surprisingly, these striking morphologic changes occurred irrespective of any cytogenetic response to STI571. Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibitfeatures resembling normal hematopoiesis.</description><identifier>ISSN: 0002-9173</identifier><identifier>PMID: 11888075</identifier><language>eng</language><publisher>England</publisher><subject>Antineoplastic Agents - therapeutic use ; Benzamides ; Biopsy ; Bone Marrow - pathology ; Cell Count ; Cell Differentiation ; Cytogenetic Analysis ; Fibrosis ; Hematopoiesis ; Hematopoietic Stem Cells - pathology ; Humans ; Imatinib Mesylate ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Megakaryocytes - pathology ; Necrosis ; Piperazines - therapeutic use ; Pyrimidines - therapeutic use</subject><ispartof>American journal of clinical pathology, 2002-03, Vol.117 (3), p.360-367</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11888075$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasserjian, Robert P</creatorcontrib><creatorcontrib>Boecklin, Federica</creatorcontrib><creatorcontrib>Parker, Sally</creatorcontrib><creatorcontrib>Chase, Andy</creatorcontrib><creatorcontrib>Dhar, Sunanda</creatorcontrib><creatorcontrib>Zaiac, Michael</creatorcontrib><creatorcontrib>Olavarria, Eduardo</creatorcontrib><creatorcontrib>Lampert, Irvin</creatorcontrib><creatorcontrib>Henry, Kristin</creatorcontrib><creatorcontrib>Apperley, Jane F</creatorcontrib><creatorcontrib>Goldman, John M</creatorcontrib><title>ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response</title><title>American journal of clinical pathology</title><addtitle>Am J Clin Pathol</addtitle><description>The tyrosine kinase inhibitor STI571 (imatinib mesylate, Gleevec) is an effective treatment for chronic myeloid leukemia (CML). We examined bone marrow samples from 53 patients with CML who were receiving STI571 in 3 multicenter phase 2 trials to assess morphologic changes and cytogenetic response to this drug. In most patients with initially increased blasts, the bone marrow blast count rapidly decreased during STI571 therapy. Reductions in cellularity, the myeloid/erythroid ratio (commonly with relative erythroid hyperplasia), and reticulin fibrosis (if present pretreatment) also were seen in most patients, resulting in an appearance resembling normal marrow in many cases. Eighteen patients (34%) had some degree of cytogenetic response. Surprisingly, these striking morphologic changes occurred irrespective of any cytogenetic response to STI571. Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibitfeatures resembling normal hematopoiesis.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Biopsy</subject><subject>Bone Marrow - pathology</subject><subject>Cell Count</subject><subject>Cell Differentiation</subject><subject>Cytogenetic Analysis</subject><subject>Fibrosis</subject><subject>Hematopoiesis</subject><subject>Hematopoietic Stem Cells - pathology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Megakaryocytes - pathology</subject><subject>Necrosis</subject><subject>Piperazines - therapeutic use</subject><subject>Pyrimidines - therapeutic use</subject><issn>0002-9173</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE9LxDAQxXtQ3HX1K0hOoodC0iZNe5TFf7Dgwd5Lmk7WSJrUJFXq1S9uFtfDvGFmfjyYd5KtMcZF3hBerrLzEN4xJkWN6Vm2IqSua8zZOvt5bQnjBN3oUURtdY9GCIsREW6Rh2GWEFDvLKBReO--kARjZiO8jgsSdkDW-VEY_Z2w0fnpzRm31xIpEHH2aal90glk1J-AnEJyiW4PFmKCDhdnA1xkp0qYAJfHvsnah_t2-5TvXh6ft3e7fGKU5XWJB0ygAco5U0AJU41SDaRZVAMUDFeUUNmXVYFpCRUntJBNSYpUA1S03GTXf7aTdx8zhNiNOhz-ERbcHDpOGMacNAm8OoJzP8LQTT6F45fuP7XyF7TFadY</recordid><startdate>200203</startdate><enddate>200203</enddate><creator>Hasserjian, Robert P</creator><creator>Boecklin, Federica</creator><creator>Parker, Sally</creator><creator>Chase, Andy</creator><creator>Dhar, Sunanda</creator><creator>Zaiac, Michael</creator><creator>Olavarria, Eduardo</creator><creator>Lampert, Irvin</creator><creator>Henry, Kristin</creator><creator>Apperley, Jane F</creator><creator>Goldman, John M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200203</creationdate><title>ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response</title><author>Hasserjian, Robert P ; Boecklin, Federica ; Parker, Sally ; Chase, Andy ; Dhar, Sunanda ; Zaiac, Michael ; Olavarria, Eduardo ; Lampert, Irvin ; Henry, Kristin ; Apperley, Jane F ; Goldman, John M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p545-830d01e9e4775fe415f9ff9ee47a6de2506414cb362043e67142c9312931de643</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Biopsy</topic><topic>Bone Marrow - pathology</topic><topic>Cell Count</topic><topic>Cell Differentiation</topic><topic>Cytogenetic Analysis</topic><topic>Fibrosis</topic><topic>Hematopoiesis</topic><topic>Hematopoietic Stem Cells - pathology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Megakaryocytes - pathology</topic><topic>Necrosis</topic><topic>Piperazines - therapeutic use</topic><topic>Pyrimidines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hasserjian, Robert P</creatorcontrib><creatorcontrib>Boecklin, Federica</creatorcontrib><creatorcontrib>Parker, Sally</creatorcontrib><creatorcontrib>Chase, Andy</creatorcontrib><creatorcontrib>Dhar, Sunanda</creatorcontrib><creatorcontrib>Zaiac, Michael</creatorcontrib><creatorcontrib>Olavarria, Eduardo</creatorcontrib><creatorcontrib>Lampert, Irvin</creatorcontrib><creatorcontrib>Henry, Kristin</creatorcontrib><creatorcontrib>Apperley, Jane F</creatorcontrib><creatorcontrib>Goldman, John M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasserjian, Robert P</au><au>Boecklin, Federica</au><au>Parker, Sally</au><au>Chase, Andy</au><au>Dhar, Sunanda</au><au>Zaiac, Michael</au><au>Olavarria, Eduardo</au><au>Lampert, Irvin</au><au>Henry, Kristin</au><au>Apperley, Jane F</au><au>Goldman, John M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response</atitle><jtitle>American journal of clinical pathology</jtitle><addtitle>Am J Clin Pathol</addtitle><date>2002-03</date><risdate>2002</risdate><volume>117</volume><issue>3</issue><spage>360</spage><epage>367</epage><pages>360-367</pages><issn>0002-9173</issn><abstract>The tyrosine kinase inhibitor STI571 (imatinib mesylate, Gleevec) is an effective treatment for chronic myeloid leukemia (CML). We examined bone marrow samples from 53 patients with CML who were receiving STI571 in 3 multicenter phase 2 trials to assess morphologic changes and cytogenetic response to this drug. In most patients with initially increased blasts, the bone marrow blast count rapidly decreased during STI571 therapy. Reductions in cellularity, the myeloid/erythroid ratio (commonly with relative erythroid hyperplasia), and reticulin fibrosis (if present pretreatment) also were seen in most patients, resulting in an appearance resembling normal marrow in many cases. Eighteen patients (34%) had some degree of cytogenetic response. Surprisingly, these striking morphologic changes occurred irrespective of any cytogenetic response to STI571. Thus, STI571 seems to affect the differentiation of CML cells in vivo, causing even extensively Philadelphia chromosome-positive hematopoiesis to exhibitfeatures resembling normal hematopoiesis.</abstract><cop>England</cop><pmid>11888075</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9173 |
| ispartof | American journal of clinical pathology, 2002-03, Vol.117 (3), p.360-367 |
| issn | 0002-9173 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71500719 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals |
| subjects | Antineoplastic Agents - therapeutic use Benzamides Biopsy Bone Marrow - pathology Cell Count Cell Differentiation Cytogenetic Analysis Fibrosis Hematopoiesis Hematopoietic Stem Cells - pathology Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Megakaryocytes - pathology Necrosis Piperazines - therapeutic use Pyrimidines - therapeutic use |
| title | ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T14%3A52%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ST1571%20(imatinib%20mesylate)%20reduces%20bone%20marrow%20cellularity%20and%20normalizes%20morphologic%20features%20irrespective%20of%20cytogenetic%20response&rft.jtitle=American%20journal%20of%20clinical%20pathology&rft.au=Hasserjian,%20Robert%20P&rft.date=2002-03&rft.volume=117&rft.issue=3&rft.spage=360&rft.epage=367&rft.pages=360-367&rft.issn=0002-9173&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E71500719%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71500719&rft_id=info:pmid/11888075&rfr_iscdi=true |